Study Title |
Protocol ID |
Disease (Sub Disease) |
Diagnosis Stage |
Location |
Links |
Status |
Trial Open Date |
Trial Close Date |
Sites |
Study Type |
Phase |
Age Eligibility |
ANZCTR |
International registry ID's |
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones |
AALL1631 |
Leukaemia (ALL) |
New diagnosis |
NSW / QLD / WA |
External Registry ≫ |
Open |
19/04/2018 |
|
Treatment |
Phase 3 |
1 year to 21 years at diagnosis |
|
NCT03007147 |
A Phase 3 Trial Investigating Blinatumomab (IND# 117467& NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy) |
AALL1731 |
Leukaemia (ALL) |
New diagnosis |
NSW / QLD / VIC / WA / SA / NZ |
External Registry ≫ |
Open |
15/10/2019 |
|
Treatment |
Phase 3 |
1 year to 31 Years |
|
NCT03914625 |
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy |
AALL1732 |
Leukaemia (ALL) |
New Diagnosis |
NSW / QLD / VIC / WA / SA / NZ |
External Registry ≫ |
Open |
28/10/2019 |
|
Treatment |
Phase 3 |
1 Year to 24 Years |
|
NCT03959085 |
Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome |
AAML1531 |
Leukaemia |
New diagnosis |
NSW / VIC / WA / NZ |
External Registry ≫ |
Open |
03/11/2015 |
|
Treatment |
Phase 3 |
90 days to 4 years |
|
NCT02521493 |
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia – Chronic Phase (CML-CP) |
AAML18P1 |
Chronic Myeloid Leukaemia |
On treatment |
VIC / WA |
External Registry ≫ |
Open |
15/07/2019 |
|
Treatment |
Phase 2 |
up to 25 years |
|
NCT03817398 |
A phase 2 study of reduced therapy for newly diagnosed average-risk WNT-driven medulloblastoma patients |
ACNS1422 |
Medulloblastoma |
New diagnosis |
NSW / WA / SA |
External Registry ≫ |
Open |
|
|
Treatment |
Phase 2 |
3 years to 22 years at the time of enrollment |
|
NCT02724579 |
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG) |
ACNS1821 |
Diffuse Intrinsic Pontine Glioma |
Newly diagnosed |
QLD |
External Registry ≫ |
Open |
05/05/2022 |
|
Treatment |
Phase 1/2 |
12 Months to 21 Years |
|
NCT05099003 |
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor |
ACNS2021 |
Brain and Spinal Tumours |
Newly diagnosed |
NSW / QLD / VIC / WA / NZ |
External Registry ≫ |
Open |
04/06/2021 |
|
Treatment |
Phase 2 |
3 Years to 30 Years |
|
NCT04684368 |
Australian Cardio-Oncology Registry |
ACOR |
All tumour types |
Newly diagnosed |
NSW / VIC / WA / SA / TAS |
|
Open |
01/09/2018 |
|
Registry |
Not applicable |
up t 35 Years |
|
|
A study to evaluate the safety and tolerability and pharmacokinetics of ACT001 in children with advanced brain and solid tumors |
ACT001-AU-002 |
Advanced brain tumour
Advanced solid tumour
|
Relapse/refractory |
NSW / QLD |
External Registry ≫ |
Open |
18/09/2019 |
|
Treatment |
Phase 1 |
1 Year to 21 Years |
ACTRN12618001934235 |
|
Patient Responses to Treatments: An Acute Leukaemia Registry; Minimal Residual Disease testing; Molecular Subtyping and Biobanking for Future Research |
Acute Leukaemia Registry |
Leukaemia |
|
NSW / QLD / VIC / WA / TAS |
|
Open |
01/04/2019 |
|
Registry |
Not applicable |
Child, Adult, Older Adult |
|
|
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors |
AGCT1531 |
Germ Cell Tumour |
New diagnosis |
NSW / QLD / VIC / WA / NZ |
External Registry ≫ |
Open |
08/05/2017 |
|
Treatment |
Phase 3 |
Various depending on risk group & consult protocol |
|
NCT03067181 |
Paediatric hepatic malignancy international therapeutic trial (PHITT) |
AHEP1531 |
Hepatoblastoma
Hepatocellular carcinoma
|
New diagnosis |
NSW / QLD / VIC / WA / NZ |
External Registry ≫ |
Open |
04/10/2018 |
|
Treatment |
Phase 2/3 |
up to 30 Years |
|
NCT03533582 |
Multicenter Open Label Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy |
ALLELE (ATA129-EBV-302) |
EBV post transplant |
Refractory |
NSW / VIC / WA |
External Registry ≫ |
Open |
29/12/2017 |
|
Treatment |
Phase 3 |
no limits |
|
NCT03394365 |
Key Adverse Events After Childhood Cancer |
ALTE03N1 |
Childhood Malignant Neoplasm |
Previously treated |
QLD / WA / SA |
External Registry ≫ |
Open |
24/03/2004 |
|
Observational |
Not applicable |
up to 21 Years |
|
NCT00082745 |
Neuropsychological and Social and Emotional and Behavioral Outcomes in Children with Cancer |
ALTE07C1 |
All Tumour Types
|
New diagnosis
Relapse/refractory |
QLD / VIC / WA / NZ |
External Registry ≫ |
Open |
15/09/2008 |
|
Psycho-social |
Not applicable |
3 Years to 21 Years |
|
NCT00772200 |
Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy |
ALTE11C2 |
Leukaemia
Lymphoma
|
Previously treated |
WA |
External Registry ≫ |
Open |
05/08/2013 |
|
Late Effects |
Not applicable |
no limits |
|
NCT01790152 |
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study |
ALTE15N2 |
Recurrent Neuroblastoma |
Relapse/refractory |
WA / NZ |
External Registry ≫ |
Open |
05/06/2017 |
|
Late Effects |
Not applicable |
5 Years to 50 Years |
|
NCT03057626 |
Neuroblastoma Biology Studies |
ANBL00B1 |
Solid tumours (Neuroblastoma) |
New diagnosis |
NSW / QLD / VIC / WA / SA / NZ |
External Registry ≫ |
Open |
06/11/2000 |
|
Biology |
Biology |
5 Years to 50 Years |
|
NCT03057626 |
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma |
ANBL1232 |
Ganglioneuroblastoma
Neuroblastoma
|
Relapse/refractory |
NSW / QLD / WA / SA / NZ |
External Registry ≫ |
Open |
28/07/2014 |
|
Treatment |
Phase 3 |
up to 18 months |
|
NCT02176967 |
A Phase 2 Randomised Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed& Refractory or Progressive Neuroblastoma |
ANBL1821 |
Solid tumours (Neuroblastoma) |
Relapse/refractory |
NSW / QLD / VIC / WA / SA / NZ |
External Registry ≫ |
Open |
28/05/2019 |
|
Treatment |
Phase 2 |
1 Year and older |
|
NCT03794349 |
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma |
ANHL1931 |
Lymphoma |
Newly Diagnosed |
NSW / QLD |
External Registry ≫ |
Open |
07/06/2021 |
|
Treatment |
Phase 3 |
2 Years and older |
|
NCT04759586 |
Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours |
ANZUP 1302 |
Germ Cell Tumour |
New diagnosis |
QLD / NZ |
External Registry ≫ |
Open |
01/02/2014 |
|
Treatment |
Phase 3 |
11 Years to 45 Years |
|
NCT02582697 |
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma |
AOST2031 |
Osteosarcoma |
Newly diagnosed |
NZ |
External Registry ≫ |
Open |
13/01/2023 |
|
Treatment |
Phase 3 |
up to 50 Years |
|
NCT05235165 |
A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML |
APAL2020D |
Acute myeloid leukemia |
Relapsed/refractory |
WA |
External Registry ≫ |
Open |
01/10/2022 |
|
Treatment |
Phase 3 |
29 Days to 21 Years |
|
NCT05183035 |
Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias |
APAL2020SC |
Leukaemia |
Relapsed/refractory |
NSW / VIC / NZ |
External Registry ≫ |
Open |
30/11/2021 |
|
Observational |
Not applicable |
up to 22 Years |
|
NCT04726241 |
Project: EveryChild A Registry and Eligibility Screening and Biology and Outcome Study |
APEC14B1 |
All Tumour Types |
|
NSW / QLD / VIC / WA / SA / NZ |
External Registry ≫ |
Open |
26/10/2015 |
|
Registry |
Not applicable |
up to 25 years |
|
NCT02402244 |
Renal Tumors Classification Biology and Banking Study |
AREN03B2 |
Renal tumours |
Newly diagnosed |
NSW / QLD / VIC / WA / NZ |
External Registry ≫ |
Open |
27/06/2007 |
|
Observational |
Not applicable |
up to 29 Years |
|
NCT00898365 |
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) |
AREN1921 |
Wilms |
New Diagnosis
Relapse |
NSW / QLD / VIC / WA / NZ |
External Registry ≫ |
Open |
18/09/2020 |
|
Treatment |
Phase 2 |
up to 30 Years |
|
NCT04322318 |
A Multicenter Open-label Phase 1b Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients with Unresectable or Metastatic BRAF V600-mutant Melanoma |
ARRAY-162-115 |
Solid tumours |
New diagnosis
Relapse/refractory
|
NSW |
External Registry ≫ |
Open |
13/08/2020 |
|
Treatment |
Phase 1 |
12 Years to 17 Years |
|
NCT03878719 |
Acute Lymphoblastic Leukaemia Subtype and Side-Effects from Treatment – Nationwide analysis of severe treatment-related toxicity in childhood leukaemia |
ASSET |
Leukaemia |
Previously treated |
NSW / VIC / WA / SA / NZ |
External Registry ≫ |
Open |
20/08/2015 |
|
Registry |
Not applicable |
up to 18 years |
|
|
A randomised and open-label and active controlled and safety and extrapolated efficacy study in paediatric subjects requiring anticoagulation for the treatment of a venous thromboembolic event (Phase IV) Apixaban |
B0661037 |
Venous Thromboembolism |
New Diagnosis
Relapse/Refractory |
NSW |
External Registry ≫ |
Open |
02/08/2018 |
|
Treatment |
Phase 4 |
3 Months to 17 Years |
|
NCT02464969 |
A Phase 1/2 Single-arm Study to Evaluate the Safety Pharmacokinetics and Antitumor Activity of Avapritinib in Pediatric Patients with Solid Tumors Dependent on KIT or PDGFRA Signaling |
BLU-285-3101 |
Solid tumours |
Relapse/refractory
|
NSW / VIC |
External Registry ≫ |
Open |
14/10/2022 |
|
Treatment |
Phase 1/2 |
2 Years to 17 Years |
|
NCT04773782 |
Analysis of Total Busulfan Exposure for Once Daily Intravenous Dosing in Paediatric Haematopoietic Stem Cell Transplantation- An ANZCHOG Pilot Study |
Bu4Day-PK-2016 |
Haematopoietic Stem Cell Transplant |
Newly diagnosed
Relapsed/refractory |
NSW / QLD / WA |
External Registry ≫ |
Open |
29/05/2017 |
|
Observational |
Pilot |
up to 18 years |
ACTRN12617000227392 |
|
A Phase 1/2 Study of the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma |
CA224-069 |
Lymphoma |
Relapsed/Refractory |
QLD / WA |
External Registry ≫ |
Open |
01/11/2022 |
|
Treatment |
Phase 1/2 |
up to 30 Years |
|
NCT05255601 |
A Randomized Open-Label Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing’s Sarcoma |
CAMPFIRE- J1S-MC-JP04 |
Ewing Sarcoma |
Relapsed/refractory |
VIC |
External Registry ≫ |
Open |
10/09/2022 |
|
Treatment |
Phase 2 |
1 Year to 39 Years |
|
NCT05440786 |
Developing genetically modified TCells for the treatment of paediatric solid tumours |
CARTpaedST |
Solid tumours |
New diagnosis |
|
|
Open |
08/04/2018 |
|
Treatment |
Phase 1 |
up to 18 years |
|
|
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy |
CCTL019A2205B |
|
Previously treated |
VIC |
External Registry ≫ |
Open |
02/11/2015 |
|
Observational |
Not applicable |
Child, Adult, Older Adult |
|
NCT02445222 |
Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone and Mitoxantrone and PEG-asparaginase& and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblastic Leukaemia |
CFZ2008 / 20140106 |
Acute Lymphoblastic Leukaemia (ALL) |
Relapse/refractory |
NSW / QLD / VIC / WA |
External Registry ≫ |
Open |
10/09/2015 |
|
Treatment |
Phase 1/2 |
1 Month to 21 Years |
|
NCT02303821 |
A phase i/ii open-label single-arm two-part trial to evaluate safety tolerability pharmacokinetics and anti-tumor activity of glofitamab in combination with chemoimmunotherapy in pediatric and young adult participants with relapsed/refractory mature b-cell non-hodgkin lymphoma |
CO43810 |
Non-hodgkin lymphoma |
Relapsed/refractory |
QLD |
External Registry ≫ |
Open |
16/11/2022 |
|
Treatment |
Phase 1/2 |
6 Months to 30 Years |
|
NCT05533775 |
A pilot and surgical study of larotrectinib for treatment of children with newly-diagnosed high-grade glioma with NTRK fusion |
CONNECT1903 |
Brain and Spinal Tumours (High Grade Gliomas) |
New diagnosis |
NSW / QLD / WA |
External Registry ≫ |
Open |
08/04/2021 |
|
Treatment |
Pilot |
up to 21 years |
|
NCT04655404 |
Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (tocilizumab) for the treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma |
CONNECT1905 |
Adamantinomatous Craniopharyngioma |
Relapsed/refractory |
WA |
External Registry ≫ |
Open |
19/12/2022 |
|
Treatment |
Phase 2 |
1 Year to 25 Years |
|
NCT05233397 |
Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma |
CONNECT2108 |
Adamantinomatous Craniopharyngioma |
Relapsed/refractory |
WA |
External Registry ≫ |
Open |
08/05/2023 |
|
Treatment |
Phase 2 |
1 Year to 25 Years |
|
NCT05286788 |
A Phase 1 Open-label Parallel Group Study to Investigate Olaparib Safety andTolerability Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours |
D0816C00025 |
Solid Tumours |
Relapsed/refractory |
WA |
External Registry ≫ |
Open |
01/11/2022 |
|
Treatment |
Phase 1 |
0 Years to 18 Years |
|
NCT04236414 |
A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With BRAF-Altered Recurrent or Progressive Low-Grade Glioma |
DAY101-001 (FIREFLY) |
Low-grade Glioma |
Relapse/refractory |
QLD |
External Registry ≫ |
Open |
17/03/2021 |
|
Treatment |
Phase 2 |
6 Months to 25 Years |
|
NCT04775485 |
International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository |
DIPG |
Diffuse Intrinsic Pontine Glioma |
|
QLD / WA / NZ |
External Registry ≫ |
Open |
30/06/2012 |
|
Registry |
Not applicable |
Child, Adult, Older Adult |
|
NCT03101813 |
A Phase 3 Open-label Multicenter Study of the Safety Efficacy and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Pediatric Patients <12 Years of Age With Severe Hemophilia A |
EFC16295 |
Hemophilia A |
Recurrent/ refractory |
QLD |
External Registry ≫ |
Open |
19/02/2021 |
|
Treatment |
Phase 3 |
up to 12 years |
|
NCT04759131 |
Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue |
HeadStart4 |
Medulloblastoma
PNET |
Newly diagnosed |
NZ |
External Registry ≫ |
Open |
01/09/2015 |
|
Treatment |
Phase 4 |
up to 10 Years |
|
NCT02875314 |
Post mortem tumour donation for Diffuse Intrinsic Pontine Glioma – developing DIPG cell cultures to test novel therapeutic strategies |
HoTRODS |
Diffuse Pontine Glioma
Diffuse Midline Glioma
High grade glioma |
New Diagnosis
Relapse |
NSW / WA |
External Registry ≫ |
Open |
17/07/2012 |
|
Observational |
Not applicable |
no limits |
ACTRN12612001183875 |
|
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)(HR-NBL2) |
HR NBL2 |
Neuroblastoma |
Newly diagnosed |
NSW |
External Registry ≫ |
Open |
05/11/2019 |
|
Treatment |
Phase 3 |
up to 20 years |
|
NCT04221035 |
A Phase I/II Open-Label Multicenter Study Evaluating the Safety Pharmacokinetics and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available |
iMATRIX (GO42286) |
Solid tumours |
Relapse/refractory |
NSW / VIC |
External Registry ≫ |
Open |
26/07/2021 |
|
Treatment |
Phase 1/2 |
up to 17 Years |
|
NCT04774718 |
Exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies |
INFORM2 NivEnt |
CNS Tumour
Solid Tumour |
Recurrent/ refractory
|
NSW / VIC / WA |
External Registry ≫ |
Open |
26/07/2019 |
|
Treatment |
Phase 1/2 |
6 Years to 21 Years |
|
NCT03838042 |
International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis |
LCH-IV |
Langerhans Cell Histiocytosis |
New diagnosis |
NSW / QLD / VIC / WA / NZ / TAS |
External Registry ≫ |
Open |
14/04/2014 |
|
Treatment |
Phase 3 |
up to 18 years |
|
NCT02205762 |
Liquid biopsies for molecular monitoring of paediatric solid tumours |
LIBIO |
Solid tumours |
|
NSW |
|
Open |
09/04/2019 |
|
Biology |
Not applicable |
up to 25 years |
|
|
European Low and Intermediate Risk Neuroblastoma – A SIOPEN Study |
LINES |
Solid tumours(Neuroblastoma) |
New diagnosis |
NSW / VIC / WA |
External Registry ≫ |
Open |
31/05/2019 |
|
Treatment |
Phase 3 |
90 days to 18 Years |
|
NCT01728155 |
A Phase I/II Study of the Oral RET inhibitor LOXO 292 in Paediatric patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumours |
LOXO-RET-18036 |
Brain and Spinal Tumours |
Relapse/ refractory |
NSW / VIC |
External Registry ≫ |
Open |
01/07/2019 |
|
Treatment |
Phase 1/2 |
6 months to 21 years |
|
NCT03899792 |
A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors |
LOXO-TRK-15003 |
Solid tumours |
New diagnosis
Relapse/ refractory |
NSW |
External Registry ≫ |
Open |
11/09/2017 |
|
Treatment |
Phase 1/2 |
up to 21 years |
|
NCT02637687 |
A Phase 3 Open-label Multicenter Study of the Long-term Safety and Efficacy of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients With Severe Hemophilia A |
LTS16294 |
Hemophilia
|
Previously treated |
QLD |
External Registry ≫ |
Open |
23/02/2022 |
|
Treatment |
Phase 3 |
Child, Adult, Older Adult |
|
NCT04644575 |
A Single Arm Open-Label Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms |
M20-429 |
Indolent Non-Hodgkin Lymphoma |
Relapsed/refractory |
NSW / VIC / WA |
External Registry ≫ |
Open |
29/09/2022 |
|
Treatment |
Phase 1/2 |
1 Year to 21 Year5 |
|
NCT05206357 |
Phase III randomized double-blind placebo-controlled trial of metformin for cognitive recovery and white matter growth in paediatric medulloblastoma patients |
MetMED |
Medulloblastoma |
Previously treated |
NSW / VIC |
External Registry ≫ |
Open |
28/09/2022 |
|
Treatment |
Phase 3 |
7 years to 17 years |
ACTRN12622000045718 |
|
A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced and relapsed or refractory solid tumor or lymphoma |
MK-3475-051 |
Solid Tumour
Lymphoma |
Relapse/ refractory |
NSW / QLD / VIC |
External Registry ≫ |
Open |
04/04/2016 |
|
Treatment |
Phase 1/2 |
6 months to 17 years |
|
NCT02332668 |
Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting with Spinal Canal Involvement (SCI) |
NB SCI Registry |
Neuroblastoma |
|
NSW / QLD / VIC / WA / SA / TAS |
External Registry ≫ |
Open |
01/04/2015 |
|
Registry |
Not applicable |
up to 18 Years |
|
NCT02559804 |
PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib |
ON TRK |
Solid tumours (NTRK Gene Fusion) |
|
NSW |
External Registry ≫ |
Open |
03/04/2020 |
|
Observational |
Not applicable |
no limits |
|
NCT04142437 |
A phase II & open-labeled & multi-center & randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naive children with unresectable or progressive low grade glioma |
OZM-063 (LGG Avastin) |
Brain and Spinal Tumours(Low Grade Gliomas) |
New diagnosis
Relapse/ refractory |
NSW / QLD / VIC / WA / SA / NZ |
External Registry ≫ |
Open |
29/05/2018 |
|
Treatment |
Phase 2 |
6 months to 18 years old |
|
NCT02840409 |
Phase 2/3 Multicenter Randomized Double-Blind Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV BKV CMV EBV HHV-6 and JCV Infection and/or Disease in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant. |
P-105-202 |
|
|
QLD |
External Registry ≫ |
Open |
31/03/2023 |
|
Observational |
Phase 3 |
Child, Adult, Older Adult |
|
NCT05305040 |
Phase I clinical trial of adoptive transfer of multi-virus-specific T cells into TCRaß+/CD19+-depleted haploidentical HSCT recipients |
P3505 |
Haematological diseases |
New Diagnosis
Relapse/Refractory |
QLD / VIC |
External Registry ≫ |
Open |
17/06/2020 |
|
Supportive Care |
Phase 1 |
3 months to 18 years |
ACTRN12620000141943 |
|
A combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGS) at Initial Diagnosis Post-Radiation Therapy and at Time of Progression |
PNOC022 |
Diffuse Midline Glioma |
Newly diagnosed
Relapsed/Refractory |
NSW / QLD / VIC / WA / SA / NZ |
External Registry ≫ |
Open |
18/08/2022 |
|
Treatment |
Phase 1/2 |
2 Years to 39 Years |
|
NCT05009992 |
A Pivotal Phase 1/2 Single-Arm Open-label Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy or Who Have the T315I Mutation |
Ponatinib-1501 /AALL1922 |
Leukaemia (ALL) |
Relapse/ refractory |
QLD / VIC / WA |
External Registry ≫ |
Open |
21/02/2021 |
|
Treatment |
Phase 1/2 |
1 Year to 21 Years |
|
NCT04501614 |
International Pleuropulmonary Blastoma Registry for PPB DICER1 and Associated Conditions |
PPB DICER |
Pleuropulmonary Blastoma |
|
NSW / WA |
External Registry ≫ |
Open |
06/12/2015 |
|
Registry |
Not applicable |
Child, Adult, Older Adult |
|
NCT03382158 |
Assessment of the Utility of Family-based (Trio) Whole-genome Sequencing for Cancer Predisposition Testing in Sequential Newly Diagnosed Paediatric and Adolescent Cancer Patients |
PREDICT |
All tumour types |
Newly diagnosed |
NSW |
External Registry ≫ |
Open |
08/03/2021 |
|
Observational |
Not applicable |
up to 21 years |
|
NCT04903782 |
PRecISion Medicine for Children with Cancer |
PRISM |
All Tumour Types |
New Diagnosis
Relapse/ Refractory |
NSW / QLD / VIC / WA / SA |
External Registry ≫ |
Open |
05/09/2017 |
|
Biology |
Biology |
up to 21 years |
|
NCT03336931 |
A phase 1 trial of HLA-DR matched third party donor-derived fungus-specific cytotoxic T-lymphocytes in patients with invasive fungal disease post-allogeneic stem cell transplantation |
R3ACT Fungal |
Invasive Fungal Disease |
Newly diagnosed
Relapsed/Refractory |
NSW |
External Registry ≫ |
Open |
19/08/2019 |
|
Treatment |
Phase 1 |
1 Years to 80 Years |
ACTRN12618001540202 |
|
A Phase II Canadian Pediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma |
ReRAD |
Brain and Spinal Tumours |
Relapsed/ refractory |
NSW / QLD / VIC / WA / NZ |
External Registry ≫ |
Open |
15/04/2017 |
|
Treatment |
Phase 2 |
up to 17 years |
|
NCT03126266 |
International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma |
RG_13-277 (rEECur) |
Solid tumours (Ewings sarcoma) |
Relapse/ refractory |
NSW / QLD / VIC / WA / SA / NZ |
External Registry ≫ |
Open |
03/04/2018 |
|
Treatment |
Phase 2/3 |
4 years to 50 years |
ACTRN12618001825246 |
|
An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma |
RG_17-427 (FaR-RMS) |
Rhabdomyosarcoma |
Relapsed/ refractory |
NSW / VIC / WA / NZ |
External Registry ≫ |
Open |
17/09/2020 |
|
Treatment |
Phase 1 |
no limits |
|
NCT04625907 |
A multicentre study of SARS-CoV-2 infection in children with cancer immunodeficiency or following stem cell transplant |
SARS-CoV-2 |
All tumour types |
|
NSW / QLD / VIC / WA / SA / NZ / TAS |
|
Open |
14/04/2020 |
|
Registry |
Not applicable |
up to 21 Years |
|
|
Using single-cell RNA-sequencing to identify clonal enrichment in paediatric solid tumours |
SCRIPT |
Solid tumours |
|
NSW |
|
Open |
20/07/2018 |
|
Biology |
Not applicable |
up to 18 years |
|
|
International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia (A randomized Phase III study conducted by the AIEOP-BFM study group) |
Study10 |
Lymphoblastic leukaemia |
Newly diagnosed |
NSW |
External Registry ≫ |
Open |
15/07/2018 |
|
Treatment |
Phase 3 |
up to 17 Years |
|
NCT03643276 |
A TACL Phase 1/2 Study of PO Ixazomib in combination with chemotherapy for childhood relapsed or refractory ALL and Lymphoblastic Lymphoma (Takeda) |
T2017-002 |
Leukaemia (ALL) |
Relapsed/ refractory |
NSW |
External Registry ≫ |
Open |
12/02/2019 |
|
Treatment |
Phase 1/2 |
1 Year to 21 Years |
|
NCT03817320 |
A retrospective cohort study of response and survival in pediatric patients with relapsed and refractory acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LLy) treated with contemporary salvage therapy |
T2018-001 |
Leukaemia (ALL)
Lymphoma (LLy) |
Relapsed/refractory |
NSW |
|
Open |
01/01/2022 |
|
Observational |
Not applicable |
up to 21 years |
|
|
Safety and oversight of the individually tailored treatment approach: A novel pilot study |
TAILOR |
All tumour types |
Newly diagnosed
Relapsed/Refractory |
VIC |
External Registry ≫ |
Open |
01/06/2021 |
|
Treatment |
Pilot |
2 Years and older |
|
NCT04801966 |
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial |
TAPISTRY |
All tumour types |
Relapsed/ refractory |
NSW / VIC |
External Registry ≫ |
Open |
18/01/2021 |
|
Treatment |
Phase 2 |
no limits |
|
NCT04589845 |
A phase II study of trametinib in paediatric adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas |
TiNT |
Solid tumours (Other Solid Tumour) |
Relapsed/ refractory |
NSW / QLD / VIC / WA / SA / NZ / TAS |
External Registry ≫ |
Open |
01/03/2021 |
|
Treatment |
Phase 2 |
3 Months to 25 Years |
ACTRN12620001229965 |
|
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma |
TOTAL 17 |
Leukaemia
Lymphoma |
Newly diagnosed |
VIC |
External Registry ≫ |
Open |
01/12/2021 |
|
Treatment |
Phase 2/3 |
1 Year to 18 Years |
|
NCT03117751 |
A phase 1/2 open-label safety tolerability pharmacokinetics and anti-tumour activity study of repotrectinib in paediatric and young adult subjects with advanced or metastatic malignancies harbouring ALK ROS1 or NTRK1-3 alterations |
TPX-0005-07 |
Solid tumours |
Relapsed/ refractory |
NSW / QLD / WA |
External Registry ≫ |
Open |
20/03/2020 |
|
Treatment |
Phase 1/2 |
up to 25 years |
|
NCT04094610 |
Precision Medicine for Every Child With Cancer |
ZERO2 |
All tumour types
|
Newly diagnosed
Relapsed/Refractory |
NSW |
External Registry ≫ |
Open |
16/12/2022 |
|
Observational |
Not applicable |
0 Years to 25 Years |
|
NCT05504772 |